Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 583-587

  Ljungman, P ^a   Lore K ^a   Aschan, J ^a   Klaesson, S ^a   Lewensohn Fuchs, I ^a   Lonnqvist B ^a   Ringden O ^a   Winiarski, J ^a   Ehrnst, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiviral therapy; BMT; Cytomegalovirus; Semi quantitative PCR

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; VIRUS DNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FATALITY; DYSURIA; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY;

ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FOSCARNET; GANCICLOVIR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; INCIDENCE; LEUKOCYTES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIREMIA; VIRUS ACTIVATION;

EID: 15844429139     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373-380.
2. Goodrich JM, Mon M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
3. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. New Engl J Med 1991; 324: 1005-1011.
4. Ehrnst A, Barkholt L, Levensohhn-Fuchs I et al. CMV PCR monitoring in leukocytes of transplant patients. Clin Diagnost Virol 1995; 3: 139-153.
5. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-753.
6. Ringdén O, Remberger M, Persson U, Ljungman P et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR compatible unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
7. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graftversus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
8. Porter-Jordan K, Rosenberg E, Keiser J et al. Nested polymerase chain reaction assay for the detection of cytomegalovirus overcomes false positives caused by contamination with fragmented DNA. J Med Virol 1990; 30: 85-91.
9. Goodrich J, Bowden R, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
10. Winston D, Ho W, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
11. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994: 83: 1971-1979.
12. Ljungman P, Aschan J, Azinge JN et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993; 83: 118-124.
13. Ehrnst A, Barkholt L, Brattström C et al. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993: 39: 118-124.
14. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
15. Einsele H, Steidle M, Valbracht A et al. Early occurrence of HCMV infection after BMT as demonstrated by the PCR technique. Blood 1991; 77: 1104-1110.
16. Vlieger A, Boland G, Jiwa N et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992; 9: 247-253.